AstraZeneca's ANDROMEDA trial is a pivotal Phase I/II study evaluating AZD9750, an innovative AR-PROTAC, in patients with metastatic prostate cancer. The trial's modular design allows for flexible assessment of AZD9750 both as a monotherapy and in combination with saruparib, a PARP1-selective inhibitor. Given the increasing prevalence of prostate cancer and the limitations of current therapies, successful outcomes could position AZD9750 as a significant player in the oncology market, particularly in the treatment of resistant forms of prostate cancer. The competitive landscape includes established therapies such as AR antagonists and taxanes, but AZD9750's unique mechanism may provide a differentiated therapeutic option. Diligence should focus on the trial's safety and efficacy data, as well as potential regulatory pathways and market access strategies.